Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I.

Pollak, M N

Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. [electronic resource] - Anticancer research - 889-91 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

0250-7005


Adult
Aged
Arginine
Breast Neoplasms--drug therapy
Colonic Neoplasms--drug therapy
Female
Growth Hormone--blood
Humans
Insulin-Like Growth Factor I--analysis
Kidney Neoplasms--drug therapy
Middle Aged
Neoplasms--drug therapy
Octreotide--therapeutic use
Ovarian Neoplasms--drug therapy
Pancreatic Neoplasms--drug therapy
Somatomedins--analysis